Unibest
← Back to patent-cliff list

MRX-2843

Tier C — Watch / trade

MRX-2843

University Of North Carolina At Chapel Hill
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:FLT3, MerTK

Indications (approved):Acute myeloid leukaemia, Leukaemia, Acute lymphoblastic leukaemia, Non-small cell lung cancer, Lung cancer, Solid tumour, 病理过程, 肿瘤形成过程

Regional status

US
Phase I
2018-05-22
EU
-
China
Phase II
2021-07-01
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 4 · Total yield /
MRX-28431429882-07-4MRX-2843-0011060816-58-1MRX-2843-002103202-62-6MRX-2843-003176325-83-0MRX-2843-00462893-54-3MRX-2843-0051621619-16-6MRX-2843-006763120-62-3MRX-2843-007—API · MRX-2843
CodeCAS No.Intermediate
MRX-28431429882-07-4-
MRX-2843-0011060816-58-15-bromo-2-chloro-7H-pyrrolo[2,3-d]pyrimidine
MRX-2843-002103202-62-6(1s,4s)-4-((tert-butyldimethylsilyl)oxy)cyclohexanol
MRX-2843-003176325-83-05-bromo-7-((1r,4r)-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2-chloro-7H-pyrrolo[2,3-d]pyrimidine
MRX-2843-00462893-54-32-cyclopropylethanamine
MRX-2843-0051621619-16-65-bromo-7-((1r,4r)-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)-N-(2-cyclopropylethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
MRX-2843-006763120-62-3(4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid
MRX-2843-007-7-((1r,4r)-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)-N-(2-cyclopropylethyl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine

Frequently asked questions

What are the approved indications of MRX-2843?

Approved indications include: Acute myeloid leukaemia, Leukaemia, Acute lymphoblastic leukaemia, Non-small cell lung cancer, Lung cancer, Solid tumour, 病理过程, 肿瘤形成过程.

When does the MRX-2843 patent expire?

No public expiry year is available for MRX-2843 yet; this page updates once verified.

How many synthesis routes are recorded for MRX-2843?

1 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy MRX-2843 intermediates?

All intermediates in MRX-2843 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for MRX-2843 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-06